A convergent picture is emerging in Alzheimer's Disease research that positions oxidative stress, chronic neuroinflammation, and mitochondrial dysfunction not as isolated hallmarks but as an interlocking pathogenic circuit that both initiates and sustains disease progression. Mitochondrial dysfunction and disrupted mitochondrial dynamics/homeostasis compromise ATP production and calcium handling, generating reactive oxygen species that disrupt neuronal integrity and converge with cellular stress responses to impair spliceosomal fidelity and RNA-binding protein function. Endoplasmic reticulum stress, acting through IRE1α signaling, forms a pivotal node connecting cellular stress to neuroinflammation, while glial dysfunction and microglial polarization fail to resolve inflammation, creating a self-reinforcing pathogenic feedback loop in which oxidative stress and neuroinflammation perpetuate one another—termed the redox-neuroinflammatory nexus. This loop is further amplified by peripheral immune cell infiltration, NLRP3 inflammasome activation (itself modulated by gut microbiota composition and dysbiosis), and interactions with vascular dysfunction, collectively exacerbating amyloid-beta deposition, tau pathology, and downstream neuronal injury.
Therapeutic trajectories are diversifying beyond classical amyloid- and tau-centric approaches toward upstream modulation of these convergent stress pathways. RNA-based technologies and antisense oligonucleotides are being developed to restore transcriptomic balance and directly modify disease progression by targeting dysregulated RNA processing. Simultaneously, lifestyle and dietary interventions—validated across multiple transgenic models (3xTg-AD, Tg2576, APP/PS1)—demonstrate that nutrition modulates β-amyloid accumulation, tau aggregation, and neuroinflammatory tone, while exercise alleviates ER stress and inhibits IRE1α overactivation, reinforcing lifestyle modification as a clinically actionable strategy, particularly when enabled by earlier diagnosis. Microglial polarization and glycosylase inhibitors represent additional nodes for therapeutic modulation aimed at dampening maladaptive inflammation without eliminating protective glial function.
A parallel trend is the computational and precision-medicine turn: artificial intelligence is being integrated with multi-omics and structure-guided drug design to enable individualized therapeutic strategies that account for patient-specific genetic risk (e.g., Apolipoprotein E4), metabolic status, and microbiome composition. Together, these threads suggest a field-wide shift from single-target amyloid/tau therapeutics toward systems-level interventions—spanning gut-brain-immune axes, RNA metabolism, mitochondrial quality control, and redox-inflammatory signaling—reflecting growing consensus that Alzheimer's Disease is a multi-hit, feedback-driven disorder requiring combinatorial and personalized intervention strategies rather than single-mechanism cures.